Overview

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Status:
RECRUITING
Trial end date:
2026-06-26
Target enrollment:
Participant gender:
Summary
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Junshi Bioscience Co., Ltd.